385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results

• Ajay Gopal,
• Mahesh Seetharam,
• Alex Adjei,
• Linda Lee,
• Wael Harb,
• Jordan Berlin,
• Yan Xing,
• Paul Swiecicki,
• Lakshminarayanan Nandagopal,
• Cong Xu,
• Yuan Meng,
• Yonggang Zhao,
• Zhengyi Wang,
• Joan Huaqiong Shen

Affiliations

Ajay Gopal

7University of Washington, Seattle, WA, USA

Mahesh Seetharam

3Mayo Clinic, Rochester, MN, USA

Alex Adjei

3Mayo Clinic, Rochester, MN, USA

Linda Lee

8I-Mab Biopharma, Gaithersburg, MD, USA

Wael Harb

2Horizon Oncology Center, Lafayette, IN, USA

Jordan Berlin

1Vanderbilt University, Nashville, TN, USA

Yan Xing

4City of Hope, Duarte, CA, USA

Paul Swiecicki

5University of Michigan, Ann Arbor, MI, USA

Lakshminarayanan Nandagopal

6University of Alabama, Birmingham, AL, USA

Cong Xu

8I-Mab Biopharma, Gaithersburg, MD, USA

Yuan Meng

8I-Mab Biopharma, Gaithersburg, MD, USA

Yonggang Zhao

8I-Mab Biopharma, Gaithersburg, MD, USA

Zhengyi Wang

8I-Mab Biopharma, Gaithersburg, MD, USA

Joan Huaqiong Shen

8I-Mab Biopharma, Gaithersburg, MD, USA